Roche committed to innovation and growth
5 September 2012 | By Roche
Personalised healthcare leadership and world-class pipeline presented at investor conference...
List view / Grid view
5 September 2012 | By Roche
Personalised healthcare leadership and world-class pipeline presented at investor conference...
28 August 2012 | By Roche
Daniel O’Day appointed new Head of Roche Pharma– Roland Diggelmann will assume the position Head of Roche Diagnostics...
27 August 2012 | By Roche
Pivotal study met co-primary efficacy endpoint of overall survival...
13 August 2012 | By Roche
First major treatment advance in more than 25 years for sight-threatening condition...
10 August 2012 | By Roche
Phase III study met its co-primary endpoint...
27 July 2012 | By Roche
Data will be submitted to health authorities globally...
26 July 2012 | By Roche
Fully automated assay for widely available platforms offers labs efficient solution to help assess patient vitamin D levels...
23 July 2012 | By Roche
Almost four times as many patients achieve remission with RoActemra (tocilizumab) compared to Humira (adalimumab)...
19 July 2012 | By Roche
The system will be available in the United States in the second half of 2012...
27 June 2012 | By Roche
Roche site in Nutley (New Jersey, USA) to be closed – respective R&D activities to be consolidated in Switzerland and Germany...
22 June 2012 | By Roche
“We are pleased that Perjeta helped people with HER2-positive metastatic breast cancer..."
19 June 2012 | By Roche
Roche and Seaside Therapeutics have entered into a collaboration...
15 June 2012 | By Roche
Over 20,000 employees of Roche marked the International Day of the African Child...
11 June 2012 | By Roche
Roche announced that the U.S. FDA has approved PerjetaTM (pertuzumab)...
6 June 2012 | By Roche
Data announced from the ADACTA study...